Purpose

Investigators at Boston Children's Hospital are conducting research in order to better understand the genetic factors which may contribute to epilepsy and related disorders. These findings may help explain the broad spectrum of clinical characteristics and outcomes seen in people with epilepsy.

Conditions

Eligibility

Eligible Ages
All ages
Eligible Sex
All
Accepts Healthy Volunteers
No

Criteria

For Gene-STEPS:

inclusion: seizure onset at less than 12 months of age, must be enrolled within 6 weeks
of first seizure-related presentation to BCH exclusion: simple febrile seizures, provoked
seizures, genetic or acquired cause already identified, MRI findings consistent with
specific genetic etiology

For BCH CRDC:

inclusion: diagnosis of epilepsy, patient at BCH exclusion: existing genetic diagnosis or
known cause for epilepsy, structural malformation of the brain

For Core cohort:

inclusion: diagnosis of epilepsy exclusion: existing genetic diagnosis or known cause for
epilepsy, structural malformation of the brain

For Phenotyping cohort:

inclusion: diagnosis of a genetic epilepsy exclusion: no genetic diagnosis or diagnosis
of other genetic condition that does not include epilepsy phenotype

Study Design

Phase
Study Type
Observational
Observational Model
Cohort
Time Perspective
Cross-Sectional

Arm Groups

ArmDescriptionAssigned Intervention
BCH Children's Rare Disease Cohort (CRDC) Individuals with epilepsy, onset at any age. Must be followed clinically at Boston Children's Hospital. Research trio-based exome and/or whole genome with CLIA confirmation of diagnostic findings. Exclusions include presence of existing genetic diagnosis or known cause for epilepsy, presence of structural brain malformation.
  • Genetic: Exome and/or whole genome sequencing
Gene-STEPS (Shortening Time of Evaluation in Paediatric Epilepsy Services) Collaborative effort of consortium including BCH, Great Ormond Street Hospital, Royal Children's Hospital Melbourne and Murdoch Children's Research Institute, and The Hospital for Sick Children. For BCH cohort, eligibility limited to individuals presenting clinically at BCH with seizure onset at less than 12 months of age. Must be enrolled within six weeks of first seizure-related presentation to BCH. Clinical trio-based rapid whole genome sequencing in a CLIA laboratory. Exclusions include: Simple febrile seizures, provoked seizures, genetic or acquired cause already identified, MRI findings consistent with specific genetic etiology.
  • Genetic: Exome and/or whole genome sequencing
Epilepsy Core Individuals with epilepsy, onset at any age. Research trio-based exome and/or whole genome. Exclusions include presence of existing genetic diagnosis or known cause for epilepsy, presence of structural brain malformation.
  • Genetic: Exome and/or whole genome sequencing
Phenotyping Cohort Individuals with diagnosed genetic epilepsies, including but not limited to PRRT2, SCN1A, SCN2A, SCN8A, PCDH19, SYNGAP1, DEPDC5, KCNQ2, CACNA1A.

Recruiting Locations

Boston Children's Hospital
Boston 4930956, Massachusetts 6254926 02115
Contact:
Beth Sheidley, MS,CGC
857-218-5533
PoduriLab@childrens.harvard.edu

More Details

Status
Recruiting
Sponsor
Boston Children's Hospital

Study Contact

Beth R Sheidley, MS
8572185533
beth.sheidley@childrens.harvard.edu

Detailed Description

Many individuals with epilepsy experience seizures which respond well to treatment. Some types of epilepsy, however, are characterized by seizures which begin very early in childhood and are associated with severe intellectual and/or developmental disabilities. These conditions are often difficult to treat. The investigators' research effort is focused on identifying genetic changes (known as "DNA variants") that cause epilepsy. By doing so the investigators hope to improve diagnosis and treatment for this epilepsy. We have two specific aims: 1. Identifying genetic findings in patients with epilepsy and related disorders. 2. Correlating genetic findings with epilepsy phenotypes.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.